
Instructions for Use



Mumps virus (Parotitis) IgG ELISA

Enzyme immunoassays (microtiter strips) for the gualitative and guantitative determination of IgG antibodies against Mumps virus in human serum and plasma.





Flughafenstrasse 52a D-22335 Hamburg, Germany Fax: +49 (0)40-53 28 91-11

ΤΕ Γ Ν Α ΤΙΟ Ν Α L Phone: +49 (0)40-53 28 91-0

G Μ IBL@IBL-International.com www.IBL-International.com

1. INTENDED USE

Enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgG antibodies against Mumps virus in human serum and plasma.

2. SUMMARY AND EXPLANATION

Mumps (Parotitis) is a common contagious disease with relatively moderate symptoms during childhood, but increasing complications, when adults are infected. The causative agent of mumps is a virus of the Paramyxoviridae family. Both a mumps infection or vaccination lead to a persistent immunity.

The typical symptom associated with a mumps infection is a "parotitis" (swelling of the parotid glands) and possible additional involvement of the CNS and various glandular organs (pancreas, thymus, thyroids). A mumps induced meningitis is one of the most frequent manifestations of the disease which can also appear without parotitis. The published data about the presence of meningitis vary between 1.4 % and 66 % of the clinically ill patients. In most cases there follows reconvalescence without complications.

The recognition of Mumps in the laboratory is mostly done by detection of the infectious agent itself or by the determination of virus-specific antibodies. The serodiagnosis plays a major part. Besides the classical methods like complement fixation, hemagglutination and neutralisation tests have been introduced a series of modern assays like immunofluorescence, radio immunoassay and enzyme immunoassay. The immunity of an individual is monitored by an IgG ELISA. Increasing IgG titers are helpful in the determination of the causative agent beause cross reactions with Parainfluenza-Virus type 2 may lead to a wrong interpretation of the patient reports. In the early stage of the disease, significant IgM titers may be monitored.

3. TEST PRINCIPLE

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for human IgG. After the substrate reaction the intensity of the color developed is proportional to the amount of IgG-specific antibodies detected. Results of samples can be determined directly using the standard curve.

4. WARNINGS AND PRECAUTIONS

- 1. For *in-vitro diagnostic* use only. For professional use only.
- 2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
- 3. In case of severe damage of the kit package please contact IBL or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
- 4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
- 5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
- Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details. Material Safety Data Sheets for this product are available on the IBL-Homepage or upon request directly from IBL.
- 7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
- 8. The cleaning staff should be guided by the professionals regarding potential hazards and handling.
- 9. Avoid contact with Stop solution. It may cause skin irritations and burns.
- 10. Some reagents contain sodium azide (NaN₃) as preservatives. In case of contact with eyes or skin, flush immediately with water. NaN₃ may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with a large volume of water to avoid azide build-up.
- 11. All reagents of this kit containing human serum or plasma have been tested and were found negative for anti-HIV I/II, HBsAg and anti-HCV. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

5. STORAGE AND STABILITY

The kit is shipped at ambient temperature and should be stored at 2-8 °C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters.

The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8 °C.

6. SPECIMEN COLLECTION AND STORAGE

Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8 °C	-20 °C	Keep away from heat or direct sun light.
Stability:	2 days	> 2 days	Avoid repeated freeze-thaw cycles.

7. MATERIALS SUPPLIED

Quantity	Symbol	Component
1 x 12 x 8	МТР	Microtiter Plate Break apart strips. Coated with specific antigen.
1 x 15 mL	ENZCONJ IgG	Enzyme Conjugate IgG Red colored. Ready to use. Contains: anti-human IgG, conjugated to peroxidase, protein-containing buffer, stabilizers.
1 x 4 x 2 mL	CAL A-D	Standard A-D1; 10; 40; 150 U/mL. Ready to use.Standard A = Negative ControlStandard C = Weakly Positive ControlStandard D = Positive Control
1 x 60 mL	DILBUF	Contains: IgG antibodies against Mumps, PBS, stabilizers. Diluent Buffer Ready to use. Contains: PBS Buffer, BSA, < 0.1 % NaN ₃ .
1 x 60 mL	WASHBUF CONC	Wash Buffer, Concentrate (10x) Contains: PBS Buffer, Tween 20.
1 x 15 mL	TMB SUBS	TMB Substrate Solution Ready to use. Contains: TMB.
1 x 15 mL	TMB STOP	TMB Stop Solution Ready to use. 0.5 M H ₂ SO ₄ .
2 x	FOIL	Adhesive Foil For covering of Microtiter Plate during incubation.
1 x	BAG	Plastic Bag Resealable. For dry storage of non-used strips.

8. MATERIALS REQUIRED BUT NOT SUPPLIED

- 1. Micropipettes (Multipette Eppendorf or similar devices, < 3 % CV). Volumes: 5; 50; 100; 500 µL
- 2. Calibrated measures
- 3. Tubes (1 mL) for sample dilution
- 4. 8-Channel Micropipettor with reagent reservoirs
- 5. Wash bottle, automated or semi-automated microtiter plate washing system
- 6. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm)
- 7. Bidistilled or deionised water
- 8. Paper towels, pipette tips and timer

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.

- 2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
- 3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
- 4. Use a pipetting scheme to verify an appropriate plate layout.
- 5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
- 6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
- 7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components

The contents of the kit for 96 determinations can be divided into 3 separate runs. The volumes stated below are for one run with 4 strips (32 determinations).

Dilute / dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
20 mL	WASHBUF CONC	200 mL	bidist. water	1:11	Warm up at 37 °C to dissolve crystals, if necessary. Mix vigorously.	2-8 °C	8 w

10.2. Dilution of Samples

Sample	to be diluted	with	Relation	Remarks
Serum / Plasma	generally	DILBUF	1:101	e.g. 5 μL + 500 μL DILBUF
o				

Samples containing concentrations higher than the highest standard have to be diluted further.

11. TEST PROCEDURE

1.	Pipette 100 µL of each Standard and diluted sample into the respective wells of the Microtiter
	Plate. In the qualitative test only Standard B is used.
2.	Cover plate with adhesive foil. Incubate 60 min at 18-25 °C.
3.	Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 300 µL of diluted Wash
	Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
4.	Pipette 100 µL of Enzyme Conjugate into each well.
5.	Cover plate with new adhesive foil. Incubate 30 min at 18-25 °C.
6.	Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 300 µL of diluted Wash
	Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
7.	For adding of Substrate and Stop Solution use, if available, an 8-channel Micropipettor. Pipetting
	should be carried out in the same time intervals for Substrate and Stop Solution. Use positive
	displacement and avoid formation of air bubbles.
8.	Pipette 100 µL of TMB Substrate Solution into each well.
9.	Incubate 20 min at 18-25 °C in the dark (without adhesive foil).
10.	Stop the substrate reaction by adding 100 µL of TMB Stop Solution into each well. Briefly mix
	contents by gently shaking the plate. Color changes from blue to yellow.
11	Measure optical density with a photometer at 450 nm (Reference-wavelength: 600-650 nm) within
• • •	
	60 min after pipetting of the Stop Solution.

12. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls. It is recommended to participate at appropriate quality assessment trials.

In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

13. CALCULATION OF RESULTS

The evaluation of the test can be performed either quantitatively or qualitatively.

13.1. Qualitative Evaluation

The Cut-off value is given by the optical density (OD) of the Standard B (Cut-off standard). The Cut-off index (COI) is calculated from the mean optical densities of the sample and Cut-off value. If the optical density of the sample is within a range of 20 % around the Cut-off value (grey zone), the sample has to be considered as borderline. Samples with higher ODs are positive; samples with lower ODs are negative.

For a quantification, the Cut-off index (COI) of the samples can be formed as follows:

COI =	OD Sample	
	OD Standard B	

13.2. Quantitative Evaluation

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method. A good fit is provided with cubic spline or point-to-point curve, because these methods give the highest accuracy in the data calculation.

For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used).

The concentration of the samples can be read directly from the standard curve.


The initial dilution has been taken into consideration when reading the results from the graph. Results of samples of higher predilution have to be multiplied with the dilution factor.

Samples showing concentrations above the highest standard have to be diluted as described in PRE-TEST SETUP INSTRUCTIONS and reassayed.

Typical Calibration Curve

(Example. Do not use for calculation!)

		•
Standard	U/mL	OD _{Mean}
A	1	0.007
В	10	0.419
С	40	0.948
D	150	2.212



14. INTERPRETATION OF RESULTS

Method	Range	Interpretation	
Quantitativa	< 8 U/mL	negative	-
Quantitative (Standard curve)	8 – 12 U/mL	equivocal	t
(Standard curve)	> 12 U/mL	positive	0
Qualitativa	< 0.8	negative	0
Qualitative (Cut-off Index, COI)	0.8 – 1.2	equivocal	6
	> 1.2	positive	

The results themselves should not be the only reason for any therapeutical consequences. They have to be correlated to other clinical observations and diagnostic tests.

15. EXPECTED VALUES

In an in-house study, apparently healthy subjects showed the following results:

	n		nterpretatio	n
lg Isotype	n	positive	equivocal	negative
lgG	67	70.2 %	11.9 %	17.9 %

16. LIMITATIONS OF THE PROCEDURE

Specimen collection has a significant effect on the test results. See SPECIMEN COLLECTION AND STORAGE for details.

For cross-reactivities, see PERFORMANCE.

Azide and thimerosal at concentrations > 0.1 % interfere in this assay and may lead to false results.

The following blood components do not have a significant	Hemoglobin	8.0 mg/mL
effect (+/- 20 % of expected) on the test results up to the	Bilirubin	0.3 mg/mL
below stated concentrations:	Triglyceride	5.0 mg/mL

17. PERFORMANCE

Analytical Specificity (Cross Reactivity)	No cross-reactivities were found to:		Measle	es, VZV	
Precision	Mean (U/mL)	CV (%)			
Intra-Assay	49.6	8.9			
Inter-Assay	43.2	7.8			
Linearity	Range (U/mL)	Serial dilut	ion up to	Range (%)	
Linearity	1.8 – 58.9	1/16		82 - 130	
Recovery	88 – 93 %	% Recove	ry after spil	king (n = 3)	
Method Comparison	Rel. Sensitivity		> 95 %		
versus ELISA	Rel. Specificity		> 95 %		

18. PRODUCT LITERATURE REFERENCES

- 1. Chomel JJ, Robin Y, Durdilly R, Thouvenot D, Langlois M, Aymard M, Rapid direct diagnosis of mumps meningitis by ELISA capture technique, *J Virol Methods* 68(1): 97-104 (1997)
- 2. Davidkin I, Kontio M, Paunio M, Peltola H, MMR vaccination and disease elimination: the Finnish experience, *Expert Rev Vaccines 9(9):* 1045-53 (2010)
- 3. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H, Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella, *J Infect Dis.* 191(5): 719-23 (2005)
- 4. Gut JP, Lablache C, Behr S, Kirn A, Symptomatic mumps virus reinfections, J Med Virol 45(1): 17-23 (1995)
- 5. King SM, Saunders EF, Petric M, Gold R, Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients, *Bone Marrow Transplant* 17(4): 633-6 (1996)
- Krugman RD, Witte JJ, Parkman PD, Herrmann KL, Meyer HM Jr, Wende RD, Meyer BC, Dungca R, Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines, *Public Health Rep. 92(3):* 220– 222 (1977)
- 7. Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR, Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years, *Pediatr. Infect. Dis. J.* 15(8): 687-92 (1996)
- 8. Matter L, Germann D, Bally F, Schopfer K, Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination, *Eur J Epidemiol 13(1):* 61-6 (1997)
- 9. Pinsky N.A., Huddleston J.M., Jacobson R.M., Wollan P.C., Poland G.A. Effect of Multiple Freeze-Thaw Cycles on Detection of Measles, Mumps, and Rubella Virus Antibodies, *Clin Diagn Lab Immunol.* 10(1): 19-21 (2003)
- Pisón Garcés FJ, Galbe Sánchez-Ventura J, Arcauz Eguren P, Aguirre y Dabán C, Mengual Gil J, Larrad Mur L, Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine, *Aten Primaria* 15(4): 235-7 (1995)
- 11. Tharmaphornpilas P, Yoocharean P, Rasdjarmrearnsook AO, Theamboonlers A, Poovorawan Y, Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme, *J Health Popul Nutr.* 27(1): 80-86 (2009)
- 12. Tischer A, Andrews N, Kafatos G, Nardone A, Berbers G, Davidkin I, Aboudy Y, Backhouse J, Barbara C, Bartha K, Bruckova B, Duks A, Griskevicius A, Hesketh L, Johansen K, Jones L, Kuersteiner O, Lupulescu E, Mihneva Z, Mrazova M, De Ory F, Prosenc K, Schneider F, Tsakris A, Smelhausova M, Vranckx R, Zarvou M, Miller E, Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia, *Epidemiol Infect.* 135(5): 787-97 (2007)
- 13. Zäch K, Nicoara C, Germann D, Matter L. Age-related seroprevalence of measles, mumps and rubella antibodies in 1996, *Schweiz Med Wochenschr. 128(17):* 649-57 (1998)

Symbols / Symbole / Symbôles / Símbolos / Símbolos / Σύμβολα

REF	CatNo.: / KatNr.: / No Cat.: / CatNo.: / N.º Cat.: / N.–Cat.: / Αριθμός-Κατ.:
LOT	Lot-No.: / Chargen-Bez.: / No. Lot: / Lot-No.: / Lote N.º: / Lotto n.: / Αριθμός -Παραγωγή:
	Use by: / Verwendbar bis: / Utiliser à: / Usado por: / Usar até: / Da utilizzare entro: / Χρησιμοποιείται από:
\sum	No. of Tests: / Kitgröße: / Nb. de Tests: / No. de Determ.: / N.º de Testes: / Quantità dei tests: / Αριθμός εξετάσεων:
CONC	Concentrate / Konzentrat / Concentré / Concentrar / Concentrado / Concentrato / $\Sigma u\mu \pi \iota \kappa v \omega \mu \alpha$
LYO	Lyophilized / Lyophilisat / Lyophilisé / Liofilizado / Liofilizado / Liofilizzato / Λυοφιλιασμένο
IVD	In Vitro Diagnostic Medical Device. / In-vitro-Diagnostikum. / Appareil Médical pour Diagnostics In Vitro. / Dispositivo Médico para Diagnóstico In Vitro. / Equipamento Médico de Diagnóstico In Vitro. / Dispositivo Medico Diagnostico In vitro. / Ιατρική συσκευή για In-Vitro Διάγνωση.
Û	Evaluation kit. / Nur für Leistungsbewertungszwecke. / Kit pour évaluation. / Juego de Reactivos para Evaluació. / Kit de avaliação. / Kit di evaluazione. / Κιτ Αξιολόγησης.
Í	Read instructions before use. / Arbeitsanleitung lesen. / Lire la fiche technique avant emploi. / Lea las instrucciones antes de usar. / Ler as instruções antes de usar. / Leggere le istruzioni prima dell'uso. / Διαβάστε τις οδηγίες πριν την χρήση.
*	Keep away from heat or direct sun light. / Vor Hitze und direkter Sonneneinstrahlung schützen. / Garder à l'abri de la chaleur et de toute exposition lumineuse. / Manténgase alejado del calor o la luz solar directa. / Manter longe do calor ou luz solar directa. / Non esporre ai raggi solari. / Να φυλάσσεται μακριά από θερμότητα και άμεση επαφή με το φως του ηλίου.
X	Store at: / Lagern bei: / Stocker à: / Almacene a: / Armazenar a: / Conservare a: / Αποθήκευση στους:
	Manufacturer: / Hersteller: / Fabricant: / Productor: / Fabricante: / Fabbricante: / Παραγωγός:
\triangle	Caution! / Vorsicht! / Attention! / ¡Precaución! / Cuidado! / Attenzione! / Προσοχή!
	Symbols of the kit components see MATERIALS SUPPLIED. Die Symbole der Komponenten sind im Kapitel KOMPONENTEN DES KITS beschrieben.
	Voir MATERIEL FOURNI pour les symbôles des composants du kit.
Si	mbolos de los componentes del juego de reactivos, vea MATERIALES SUMINISTRADOS.
	Para símbolos dos componentes do kit ver MATERIAIS FORNECIDOS.
	Per i simboli dei componenti del kit si veda COMPONENTI DEL KIT.
	Για τα σύμβολα των συστατικών του κιτ συμβουλευτείτε το ΠΑΡΕΧΟΜΕΝΑ ΥΛΙΚΑ.

COMPLAINTS: Complaints may be submitted initially written or vocal. Subsequently they need to be filed including the test performance and results in writing in case of analytical reasons.

WARRANTY: The product is warranted to be free from material defects within the specific shelf life and to comply with product specifications delivered with the product. The product must be used according to the Intended use, all instructions given in the instructions for use and within the product specific shelf life. Any modification of the test procedure or exchange or mixing of components of different lots could negatively affect the results. These cases invalidate any claim for replacement.

LIMITATION OF LIABILITY: IN ALL CIRCUMSTANCES THE EXTENT OF MANUFACTURER'S LIABILITY IS LIMITED TO THE PURCHASE PRICE OF THE KIT(S) IN QUESTION. IN NO EVENT SHALL MANUFACTURER BE LIABLE FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING DAMAGES FOR LOST PROFITS, LOST SALES, INJURY TO PERSON OR PROPERTY OR ANY OTHER INCIDENTAL OR CONSEQUENTIAL LOSS.

IBL International GmbH Flughafenstr. 52A, 22335 Hamburg, Germany	Tel.: E-MAIL: WEB:	+ 49 (0) 40 532891 -0 Fax: -11 IBL@IBL-International.com http://www.IBL-International.com
---	--------------------------	---